Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial is a research paper published in Nature Medicine (2024). On theSindex it has a DataRank of 0.648. It has been cited 74 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.648
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Grant: 09150172010043
Victoria’s Secret Global Fund for Women’s Cancers Rising Innovator Research Grant, in Partnership with Pelotonia & AACR
MeSH Terms
Data underlying the PhD thesis: Computational approaches to dissect immunotherapy response in breast cancer
Data underlying the PhD thesis: Computational approaches to dissect immunotherapy response in breast cancer
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early triple negative breast cancer with tumor infiltrating lymphocytes: the phase II BELLINI trial
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early triple negative breast cancer with tumor infiltrating lymphocytes: the phase II BELLINI trial